Table 1.
Clinico-pathological characteristics of IBC and non-IBC samples
| All (N = 389) | IBC (N = 137) | non-IBC (N = 252) | p-value | |
|---|---|---|---|---|
| Patients’ age, years | 54 (24–89) | 50 (24–82) | 55 (24–89) | 2.08E-03 |
| Pathological type | 0.0981 | |||
| ductal | 325 | 122 (90%) | 203 (81%) | |
| lobular | 30 | 7 (5%) | 23 (9%) | |
| mixed | 14 | 3 (2%) | 11 (4%) | |
| other | 18 | 3 (2%) | 15 (6%) | |
| Dermal lymphatic tumor emboli | 4.43E-16 | |||
| absence | 123 | 29 (24%) | 94 (76%) | |
| presence | 121 | 91 (76%) | 30 (24%) | |
| Pathological grade | 5.62E-11 | |||
| 1–2 | 174 | 30 (23%) | 144 (58%) | |
| 3 | 207 | 101 (77%) | 106 (42%) | |
| Molecular subtype | 1.75E-04 | |||
| HR+/HER2- | 223 | 60 (44%) | 163 (65%) | |
| HER2+** | 82 | 42 (31%) | 40 (16%) | |
| TN | 84 | 35 (26%) | 49 (19%) | |
| Pathological complete response | ||||
| no | 59 | 59 (68%) | NA* | |
| yes | 28 | 28 (32%) | NA | |
*NA, not available; **; HER2+ positive included 12 HR+ and 30 HR- cases in IBC and 20 HR+ and 20 HR- cases in non-IBC